Trials / Recruiting
RecruitingNCT07295704
Micropulse Laser in Treatment of Initial and Refractory Cases of Center-Involved Diabetic Macular Edema
Comparative Evaluation of Micropulse Laser in Treatment of Initial and Refractory Cases of Center-Involved Diabetic Macular Edema
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- The General Authority for Teaching Hospitals and Institutes · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the effect of subthreshold 577 nm micropulse laser photocoagulation in the treatment of initial and refractory cases of Center-Involved Diabetic Macular Edema.
Detailed description
Diabetic Retinopathy (DR) is a common and specific microvascular complication of diabetes that affects 17-54% of people with diabetes aged between 49 and 60 years. Diabetic macular edema (DME) is one of the most common causes of visual loss in today's society. It affects about 10% of diabetic individuals and 29% of those who have had the condition for more than 20 years. In micropulse mode, the laser emits short pulses, thereby reducing thermal energy in the target area. This strategy has two properties: a shorter exposure time and a subvisible clinical endpoint, delivering energy by dividing the beam into a series of short pulses (100-300 µs). Every single pulse has an "on and off" duration (duty cycle (DC)), enabling tissues to cool down before the next pulse.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Micropulse Laser | All laser procedures will be performed in a darkened room. The laser will be delivered together in an 8×8 pattern mode with high density (0µm of spacing) over the entire area of macular edema, including the foveal center and unthickened (200µm) retina with no attempt to target or avoid microaneurysms. |
Timeline
- Start date
- 2025-10-15
- Primary completion
- 2026-03-30
- Completion
- 2026-03-30
- First posted
- 2025-12-22
- Last updated
- 2025-12-22
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT07295704. Inclusion in this directory is not an endorsement.